Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: Long-term results and prognostic factors

Cancer

Volumn 106, Issue 6, 2006, Pages 1372-1381

  Kreth, Friedrich W ^a   Faist, Michael ^b   Grau, Stefan ^a   Ostertag, Christoph B ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

125I; Brachytherapy; Prognostic factors; Radiosurgery; Supratentorial; WHO Grade 2 astrocytoma

Indexed keywords

IODINE 125; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRACHYTHERAPY; BRAIN TUMOR; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOSURGERY; TUMOR VOLUME; WORLD HEALTH ORGANIZATION; ADOLESCENT; CANCER STAGING; CELL TRANSFORMATION; CLASSIFICATION; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 33644844107     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21750     Document Type: Article

References (34)

1. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52:316-324.
2. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549-556.
3. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy OncologyGroup/Eastern Cooperative Oncology Group Study. J Clin Oncol. 2002;20:2267-2276.
4. Kreth FW, Faist M, Warnke PC, Rossner R, Volk B, Ostertag CB. Interstitial radiosurgery of low-grade gliomas. J Neurosurg. 1995;82:418-429.
5. Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB. Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer. 1997;79:370-379.
6. Johannesen TB, Langmark F, Lote K. Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom patients were diagnosed between 1970-1993. J Neurosurg. 2003;99:854-862.
7. Scerrati M, Roselli R, Iacoangeli M, et al. Prognostic factors in low grade (WHO Grade 2) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiatry. 1996;61:291-296.
8. Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol. 1997;15:3129-3140.
9. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15:1294-1301.
10. Krouwer GJ, Davis RL, Silver P, Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg. 1991;74:399.
11. Zulch KG. Histological typing of tumors of the central nervous system. Geneva: World Health Organization, 1979.
12. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. 2nd ed. Berlin: Springer, 1993.
13. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: McLeod M, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949:191-205.
14. Ostertag CB, Kreth FW. Iodine-125 interstitial irradiation for cerebral gliomas. Acta Neurochir (Wien). 1992;119:53-61.
15. Kreth FW, Muaceic A, Medele R, Bise K, Meyer T, Reulen HJ. The risk of haemorrhage after image guided stereotactic biopsy of intraaxial brain tumours - a prospective study. Acta Neurochir (Wien). 2001;143:539-546.
16. Kreth FW, Faist M, Rossner R, Birg W, Volk B, Ostertag CB. The risk of interstitial radiotherapy of low-grade gliomas. Radiother Oncol. 1997;43:253-260.
17. Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;457-481.
19. Cox DR. Regression model and life-tables. J Roy Stat Soc Ser B. 1972;187-220.
20. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low grade glioma: Results of a randomized phase III trial on dose response (EORTC trial 22844). Eur J Cancer. 1998;34:1902-1909.
21. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol. 1992;31:431-436.
22. Berger MS, Deliganis AV, Dobbins'J, Keles GE. The effect of extent of resection on recurrence in patients with low-grade cerebral hemisphere gliomas. Cancer. 1994;74:1784-1791.
23. Laws ER, Jr., Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 1984;61:665-673.
24. Black WC, Ling A. Is earlier diagnosis really better? The misleading effects of lead time and length biases. AJR. 1990; 155:625-630.
25. Black WC, Welch HGG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328:1237-1243.
26. Bauman G, Lote K, Larson D, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999;45:923-929.
27. Pignatti F, van den Bent M, Curran D, Debruyne C et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-2084.
28. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54:1442-1448.
29. Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A. Supratentorial grade 2 astrocytoma: biological features and clinical course. Lancet Neurol. 2003;2:395-403.
30. Shafqat S, Hedley-Whyte ET, Henson JW. Age-dependent rate of anaplastic transformation in low grade astrcytoma. Neurology. 1999;52:867-869.
31. Peraud A, Kreth FW, Wiestler O, Kleihues P, Reulen HJ. Prognostic impact of TP53 mutations and P53 protein overexpressin in supratentorial WHO Grade 2 astrocytomas and oligoastrocytomas. Clinical Cancer Res. 2002;8:1117-1124.
32. Stander M, Peraud A, Leroch B, Kreth FW. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade 2 astrocytoma or oligoastrocytoma. Cancer. 2004;101:1028-1035.
33. Plathow C, Schulz-Erntner D, Thilman C, et al. Fractionated stereotactic radiotherapy in low-grade astrocytomas: long-term outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 2003;57:996-1003.
34. Mehrkens JH, Kreth FW, Muacevic A, Ostertag CB. Long term course of WHO grade 2 astrocytomas of the Insula of Reil after I-125 interstitial irradiation. J Neurol. 2004;251:1455-1464.